- Market Growth Factors & Global Market Size.
- Leading Players & Top Segments.
- Geographic Overview.
Market growth influenced due to following factors-
- Rising incidences of target infectious diseases and genetic disorders.
- Increasing financial support for research.
- Increasing use of biomarker profiling in disease diagnostics.
Global market size-
According to research report the dPCR qPCR market is projected to reach USD 6.3 billion by 2024. The market is expected to grow at a CAGR of 8.8% from 2019 to 2024.
The major players operating in the dPCR qPCR Market are Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).
Top Market Segments-
The hospitals and diagnostic centres segment is expected to dominate the qPCR market in 2019. The large share of this segment is attributed to the increasing market availability of qPCR reagents in clinical diagnostic applications; ongoing expansion of healthcare infrastructure across emerging countries; high prevalence & incidence of target diseases; and growing awareness on the benefits of qPCR.The global dPCR and qPCR market offers significant growth potential for current and future players. The digital PCR market is consolidated in nature, with leading players acquiring small market players to gain their state-of-the-art PCR technologies and strengthen their market presence. This also helps them to strengthen their R&D and distribution network and penetrate markets in emerging nations.
For Details, Download PDF Brochure Here
Geographic Overview -
North America accounted for the largest share of the digital PCR q PCR market in 2019, followed by Europe. The large share of North American dPCR qPCR market is mainly due to the rising number of genome-based drug development activities undertaken by US-based pharmaceutical and biotechnology companies, increasing support for the development of dPCR and qPCR technologies, a growing target patient base, and the focus on early and effective disease diagnosis.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.